newsfilter
← Latest News
ACCESS Newswire·

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate CommercializationFuture Platform Expansion into CNS, Men's Health, and Anti-Nausea ESTERO, FL / ACCESS Newswire / October 1, 2025 /